MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

76.38 +1.38 (+1.84%)
Streaming Delayed Price Updated: 3:02 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
3 Reasons HAE is Risky and 1 Stock to Buy Instead
Over the last six months, Haemonetics’s shares have sunk to $75.12, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 6.1% gain. This m... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 Profitable Stocks We Find Risky
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Haemonetics (HAE) Stock Is Up, What You Need To Know
What Happened? Shares of blood products company Haemonetics (NYSE:HAE) jumped 4.1% in the afternoon session after BofA Securities upgraded its rating on the ... 
Via StockStory
News headline image
Medical Devices & Supplies - Specialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
Haemonetics (NYSE:HAE) Passes the Caviar Cruise Quality Test ↗
Via Chartmill
News headline image
3 Russell 2000 Stocks That Concern Us
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
Haemonetics Q4 Earnings Call Highlights ↗
Haemonetics (NYSE:HAE) reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies... 
Via MarketBeat
Topics Earnings
News headline image
Haemonetics (HAE) Q4 2026 Earnings Transcript ↗
Haemonetics (HAE) Q4 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026
Blood products company Haemonetics (NYSE:HAE). reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.8% year on year to $346.4 m... 
Via StockStory
News headline image
Haemonetics Earnings: What To Look For From HAE
Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results this Thursday before market hours. Here’s what to expect. Haemonetics beat... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Value Stock on Our Buy List and 2 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
Topics ETFs
News headline image
What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year ↗
This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Healthcare Stocks with Solid Fundamentals and 1 Facing Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se... 
Via StockStory
News headline image
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack
Via StockStory
News headline image
3 Reasons HAE is Risky and 1 Stock to Buy Instead
Haemonetics’s 21.4% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $65.64 per share. This was partly d... 
Via StockStory
Topics Stocks Supply Chain
News headline image
3 Profitable Stocks with Open Questions
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
5 Revealing Analyst Questions From Haemonetics’s Q4 Earnings Call
Haemonetics’ fourth quarter results were met with a negative market reaction, reflecting investor caution despite the company’s performance exceeding Wall Street’s revenue and earnings expectations.... 
Via StockStory
Topics Earnings
News headline image
HAE Q4 Deep Dive: Plasma Momentum and Hospital Weakness Shape Mixed Results
Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%... 
Via StockStory
News headline image
Haemonetics HAE Q3 2026 Earnings Call Transcript ↗
Haemonetics HAE Q3 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Haemonetics’s (NYSE:HAE) Q4 CY2025 Sales Top Estimates, Stock Soars
Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 2.7% year on year to $339 million. Its non-GAAP profit of $1.31 per share was 4.8%... 
Via StockStory
News headline image
What To Expect From Haemonetics’s (HAE) Q4 Earnings
Blood products company Haemonetics (NYSE:HAE). will be reporting earnings this Thursday before market open. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: Haemonetics (NYSE:HAE)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - specialty stocks, including Haemonetics (NYSE:HAE) and its peers. 
Via StockStory
News headline image
The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market
As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
1 Russell 2000 Stock to Keep an Eye On and 2 Facing Headwinds
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
News headline image
3 Value Stocks with Open Questions
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
1 Cash-Producing Stock Worth Your Attention and 2 Facing Challenges
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
1 Small-Cap Stock Worth Your Attention and 2 We Avoid
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
3 Low-Volatility Stocks We Think Twice About
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Why Haemonetics (HAE) Shares Are Trading Lower Today
Shares of blood products company Haemonetics (NYSE:HAE). fell 4.3% in the afternoon session after Needham downgraded the stock from 'Buy' to 'Hold', citing concerns about growing competition. 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story